 If ranibizumab produces a similar effect to pilot studies of bevacizumab in diabetic vitreous haemorrhage,1,2,3 then it has the potential to speed visual recovery and reduce the likelihood of patients requiring surgery, with the attendant costs, patient inconvenience, and operative risks. Whilst bevacizumab is a cheaper alternative to ranibizumab, it does not yet have such extensive safety data. Further, bevacizumab has to be prepared by the treating clinician or intermediate pharmacies in a dosage appropriate for intraocular use, whereas ranibizumab is provided by the manufacturer in a pre-packaged sterile syringe containing the dose designed for intraocular administration. The relative cost disparity is likely to reduce in the coming years, and a single intravitreal injection is a very small proportion of the total treatment costs for proliferative diabetic retinopathy, which consumes considerable health care resources, particularly if an eye operation is required. 